esophageal cancer
Conditions
Interventions
Sponsors
People's Hospital Affiliated to Hubei University of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patients voluntarily participated in this study and signed the informed consent, with good compliance and follow-up; 2. Patients with esophageal squamous cell carcinoma confirmed by histopathology; 3. For patients with clinical stage IIA-IV (cT1-4 b N0-N+ M0), after radical concurrent chemoradiotherapy, the radiotherapy scheme is determined by the investigator according to the patient's condition and according to the''Chinese Radiation Guidelines for Esophageal Cancer or NCCN Guidelines'', concurrent chemotherapy uses the docetaxel + cisplatin regimen (Docetaxel 25mg/m^2 i.v. d1; Cisplatin 25mg/m^2 i.v. d1, q1w, 4-6 cycles); 4. Aged 18-70 years, no gender limit; 5. ECOG PS score of 0-1; expected survival period >= 6 months; 6. No disease progression during radiotherapy and chemotherapy and 2 months after the end of radiotherapy and chemotherapy; 7. Has adequate organ and bone marrow function.
Exclusion criteria
Exclusion criteria: 1. Patients with active bleeding within 2 months; 2. Those with multiple factors that affect oral drugs (such as inability to swallow, after gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.); 3. Allergic to anlotinib APIs and excipients; 4. Patients with esophageal squamous cell carcinoma who have a stent placed in the esophagus and who are judged by the researchers to be prone to bleeding; 5. Doctors assess patients with esophageal fistula or risk of bleeding; 6. Patients with esophageal squamous cell carcinoma who cannot accept or tolerate oral drugs; 7. Patients who have undergone radiotherapy to the same part of the esophagus in the past; 8. Patients with any severe and/uncontrolled disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Countries
China
Contacts
Public ContactCao Fengjun
People's Hospital Affiliated to Hubei University of Medicine
Outcome results
None listed